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BACKGROUND Paclitaxel drug-eluting balloons (pDEB) are indicated
for PCI of in-stent restenosis (ISR), and may have a role in revascu-
larization of de-novo lesions (DNL). While the short-term efﬁcacy and
safety of pDEB has been reported from registries and a few random-
ized controlled trials, late follow-up is lacking. Thus we studied the
late efﬁcacy and safety of SequentPlease pDEB (B. Braun, Germany) in
PCI of DNL and ISR.
METHODS All 147 patients (188 lesions) undergoing PCI using pDEB at
Liverpool Hospital, Sydney from Oct 2011 to Mar 2015 were included. Ac-
cording to the PCI lesion-type, patientswere categorized into 2 groups: DNL
and ISR [prior bare-metal stent (BMS) or drug-eluting stent (DES)]. Baseline,
procedural, and clinical outcomedatawereobtained fromthedepartmental
database and treating physicians. The primary outcome was MACE: com-
posite of cardiac death, clinically driven pDEB target-lesion revasculariza-
tion (pDEB-TLR), and myocardial infarction (MI).
RESULTS Mean patient age was 6711 years (79% male), 39% pre-
sented with an acute coronary syndrome (ACS). Clinical follow up was
1.31.0 years. Lesions treated for ISR (n¼118) were more likely than
DNL (n¼70) to be in patients with diabetes mellitus (DM, 64 vs 37%;
p<0.001), impaired renal function (43 vs 20%; p<0.001), and multi-
vessel PCI (66 vs 46%; p¼0.006). Among patients with prior coronary
bypass grafting (CABG), DES ISR was more common than BMS ISR
(39% and 18%; p¼0.02). ACS patients were more likely treated for DNL
than ISR (50 vs 33%; p¼0.02). There was no difference between DNL
and ISR groups in target lesion complexity (61% type B2/C), target
lesion length (2112mm), and pDEB length (205mm). Smaller caliber
pDEBs were used for DNL compared to ISR (2.40.4 vs 2.80.6mm;
p<0.0001). For DNL compared to ISR: cardiac death was 3% vs 0%
(p¼0.06), DEB-TLR was 1% vs 12% irrespective of stent type (p¼0.02);
and respective dissection (grade D-F) rates were 7% and 5% (p¼0.56).
MACE event rates (Table 1) were similar for DNL and ISR (14 vs 25%,
p¼0.105), and for DES and BMS ISR subgroups (23 vs 27%, p¼0.55).
Cox multivariate analysis showed diabetes and prior CABG are
independent predictors of MACE in patients with ISR (HR 4.48, 1.34-
15, P¼0.015 and HR 3.22, 1.51-6.89, p¼0.003, respectively).
Table 1. Long-Term Clinical Outcomes for pDEBOutcomesDe novo
(n[70)ISR
(n[118) p-valueBMS-ISR
(n[39)DES-ISR
(n[79) p-valueCardiac
death
(%)2 (3) 0 0.06 0 0MI (%) 5 (7) 20 (17) 0.12 6 (15) 14 (18) 0.64pDEB-TLR
(%)1 (1) 15 (12) 0.02 3 (8) 12 (15) 0.22MACE (%) 8 (14) 30 (25) 0.15 9 (23) 21 (27) 0.55CONCLUSIONS In our real-world all-comer registry, pDEB appears to be a
safe and effective stent-sparing strategy for DNL in smaller caliber arteries.
pDEB use in DNL was associated with low rates of re-intervention, and had
similar MACE rates to ISR groups. DM and prior CABG predict poorer out-
comes for pDEB used in (BMS and DES) ISR.
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BACKGROUND Scoring balloons produce excellent acute results in
the treatment of in-stent restenosis, ﬁbro-calciﬁc and bifurcation le-
sions but have not been shown to affect the restenosis rate. A novel
paclitaxel-coated scoring balloon (SB) was developed and tested to
overcome this limitation.
METHODS SB were coated with paclitaxel admixed with a speciﬁc
excipient. Patients at four clinical sites in Germany and one in Brazil
with in-stent restenosis (ISR) of coronary bare metal stent (BMS) were
randomized 1:1 to treatment with either a drug-coated or uncoated SB.
Baseline and 6-month follow-up quantitative coronary angiography
was performed by an independent blinded core lab and all patients
will be evaluated clinically for up to one year. The primary endpoint
was angiographic in-segment late lumen loss (LLL). Secondary end-
points included the rate of clinically driven target lesion revasculari-
zation (TLR), composite of major adverse cardiovascular events
(MACE), stent thrombosis and other variables at two years follow-up.
RESULTS Sixty-one patients were randomized (28 uncoated and 33
drug-coated SB); mean age 65 years, males 72 %, and presence of
diabetes 39 %. At 6-month angiography, in-segment LLL was 0.48 
0.51 mm in the uncoated SB group versus 0.17  0.40 mm in the drug-
coated SB group (p¼0.01; ITT analysis). The rate of binary restenosis
was 41 % in the uncoated SB group versus 7 % in the drug-coated SB
group (p<0.01). The MACE rate at 2 years was 32 % with the uncoated
SB vs. 9 % in the drug-coated SB group (p<0.05). This difference was
primarily due to the reduced need for clinically driven TLR in the
coated SB group (3 % vs. 32 % p<0.01).
CONCLUSIONS A novel paclitaxel-coated coronary SB has been
developed and successfully used in a ﬁrst-in-human randomized
controlled trial [ClinicalTrials.gov Identiﬁer: NCT01495533].
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BACKGROUND The aim of this study was to evaluate the impact of neo-
intimal tissuecharacteristicsassessedbyOCTusinggray-scale intensity (GSI)
on treatment for in-stent restenosis (ISR) with drug-coated balloon (DCB).
METHODS Neointimal tissue characterization using OCT-based GSI
analysis was performed for a total of 25 patients with 32 ISR lesions
undergoing DCB treatment for ISR. Neointima were classiﬁed into
mature and non-mature tissue according to our previous data with
animal models and autopsy specimens.
RESULTS Of 637 regions of interest (ROI) assessed for neointimal
maturity, 248 ROIs (39%) were mature neointimal tissue. The higher
percentage of mature tissue was associated with smaller acute gain
after PCI with DCB (Figure). Clinical events and OCT ﬁndings at 6-8
month after DCB treatment for ISR lesions will be available at
presentation. Conclusions: OCT GSI analysis for neointima might
predict reactions after treatment with DCB for ISR lesions.
CONCLUSIONS OCT GSI analysis for neointima might predict re-
actions after treatment with DCB for ISR lesions.
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BACKGROUND The use of drug-eluting balloons (DEB) for the treat-
ment of in-stent restenosis (ISR) and lesions in small vessels has not
been extensively investigated in the real-life clinical practice. Ac-
cording to the most recent guidelines, the use of DEB is indicated only
for the treatment of ISR. We aim to report a three-centers “all comers”
registry on the safety and efﬁcacy of DEB in the treatment of ISR and
de novo coronary artery disease.
METHODS Consecutive patients treated with the In.Pact Falcon
(Medtronic Inc., Minneapolis, MN, USA) paclitaxel-eluting balloon
between January 2012 and November 2014 in the centers of Verona,
Mirano and Savona were retrospectively analyzed in our registry. The
measured clinical end-points were cardiac death, myocardial infarc-
tion (MI), target lesion revascularization (TLR), target vessel revas-
cularization (TVR), while procedural success was deﬁned as the ability
to reach, cross and dilate a lesion with the study device, with a re-
sidual stenosis <30% and a ﬁnal TIMI 3 ﬂow in the culprit vessel.
Primary end point of the study was the occurrence of major adverse
cardiac events (MACE), deﬁned as combination of cardiac death, MI,
and TLR, at 12 and 24 months of follow up.
RESULTS A total of 167 lesions were successfully treated in 143 pa-
tients. The mean age was 67 10 years, and 82.5% were males. The
main risk factors were represented by hypertension and dyslipidemia
while 39.4% of patients were diabetics. The 73.5% of the population
had a prior PCI and the main indication for PCI was because of ACS
(73.5% while 26.5% of patients suffered from stable angina). The
predominant indication for DEB use was ISR (75%), mainly focal
(34.1%), involving a DES in the 79% of cases. Procedural success was
achieved in 97.6%. A mean of 1.10.18 DEB were used per patient.
Bailout stenting was required in 2 lesions. No events were recorded
during the hospitalization. Long term follow up was available for
100% of the study population. The overall incidence of MACEs at 12
months was 5.6%, while at 24 months was 9.1%, with an overall event
free survival of 85%. Of interest, the primary endpoint occurred in
18% of patients treated for de novo lesions, against a 5.7% of ISR pa-
tients (p¼0.01). Patients presenting with focal restenosis had anincidence of events comparable to those with more aggressive rest-
enotic pattern (diffuse or proliferative, p¼0.71).
CONCLUSIONS Our results conﬁrm the safety and efﬁcacy at short
and long term follow up of DEBs, especially in patients presenting
with ISR. On the contrary, the use of DEB in de novo lesions is asso-
ciated with a poorer clinical outcome. Larger trials are needed to
conﬁrm our data.
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BACKGROUND drug-coated balloons (DCB) have shown to be a valu-
able alternative to stents for the treatment of in-stent restenosis, and
there is some initial evidence of their efﬁcacy for the treatment of
small coronary vessels. Newer generation DCB were developed to
overcome the reduced deliverability of the previous generation of
devices, warranting an effective drug delivery to the vessel wall.
However, the vast majority of such devices still lack of reliability due
to paucity of clinical data.
METHODS between 2012-2014 all patients intended to be treated with
this type of DCB at 9 italian centers were enrolled in this retrospective
registry. We did not have speciﬁc exclusion criteria. Coronary in-
terventions were performed following the Italian Position paper on DCB-
PCI published in 2014. Primary outcome was the occurrence of target
lesion revascularization (TLR) at the longest available follow up.
RESULTS we enrolled 247 consecutive patients/283 lesions, whose
clinical, angiographic and procedural characteristics are depicted in
Table. At the longest available clinical follow up (average 225 days,
I.Q. ranges 67 days), 5 patients suffered a TLR, all but one managed
with re-PCI (2 with another type of DCB, 2 with DES). We registered
2 cases of cardiac death (one for heart failure and one for fatal
myocardial infarction related to another vessel), 4 non-cardiac
deaths (2 malignancies and 2 intracranial hemorrhages) and no cases
of target vessel myocardial infarction/thrombosis.
